BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 22466064)

  • 1. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease.
    Cunnane SC; Schneider JA; Tangney C; Tremblay-Mercier J; Fortier M; Bennett DA; Morris MC
    J Alzheimers Dis; 2012; 29(3):691-7. PubMed ID: 22466064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The sociodemographic characteristics and dietary and blood plasma fatty acid profiles of elderly Saudi women with Alzheimer disease.
    Alsumari SR; AlNouri DM; El-Sayed MMA; El-Din MFS; Arzoo S
    Lipids Health Dis; 2019 Mar; 18(1):77. PubMed ID: 30927917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review.
    Hosseini M; Poljak A; Braidy N; Crawford J; Sachdev P
    Ageing Res Rev; 2020 Jul; 60():101043. PubMed ID: 32194194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment.
    Conquer JA; Tierney MC; Zecevic J; Bettger WJ; Fisher RH
    Lipids; 2000 Dec; 35(12):1305-12. PubMed ID: 11201991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower omega-3 fatty acid intake and status are associated with poorer cognitive function in older age: A comparison of individuals with and without cognitive impairment and Alzheimer's disease.
    Phillips MA; Childs CE; Calder PC; Rogers PJ
    Nutr Neurosci; 2012 Nov; 15(6):271-7. PubMed ID: 22824373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study.
    Snowden SG; Ebshiana AA; Hye A; An Y; Pletnikova O; O'Brien R; Troncoso J; Legido-Quigley C; Thambisetty M
    PLoS Med; 2017 Mar; 14(3):e1002266. PubMed ID: 28323825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The shift in the fatty acid composition of the circulating lipidome in Alzheimer's disease.
    Dakterzada F; Jové M; Cantero JL; Mota-Martorell N; Pamplona R; Piñoll-Ripoll G
    Alzheimers Dement; 2024 May; 20(5):3322-3333. PubMed ID: 38534027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and cingulate cortex in patients with mild cognitive impairment.
    Köbe T; Witte AV; Schnelle A; Lesemann A; Fabian S; Tesky VA; Pantel J; Flöel A
    Neuroimage; 2016 May; 131():226-38. PubMed ID: 26433119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment.
    Oulhaj A; Jernerén F; Refsum H; Smith AD; de Jager CA
    J Alzheimers Dis; 2016; 50(2):547-57. PubMed ID: 26757190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients During Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study.
    Eriksdotter M; Vedin I; Falahati F; Freund-Levi Y; Hjorth E; Faxen-Irving G; Wahlund LO; Schultzberg M; Basun H; Cederholm T; Palmblad J
    J Alzheimers Dis; 2015; 48(3):805-12. PubMed ID: 26402079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease.
    Abdullah L; Evans JE; Emmerich T; Crynen G; Shackleton B; Keegan AP; Luis C; Tai L; LaDu MJ; Mullan M; Crawford F; Bachmeier C
    Aging (Albany NY); 2017 Mar; 9(3):964-985. PubMed ID: 28333036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary fatty acids and risk for Alzheimer's disease, dementia, and mild cognitive impairment: A prospective cohort meta-analysis.
    Zhu RZ; Chen MQ; Zhang ZW; Wu TY; Zhao WH
    Nutrition; 2021 Oct; 90():111355. PubMed ID: 34218119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolites Associated with Early Cognitive Changes Implicated in Alzheimer's Disease.
    Darst BF; Huo Z; Jonaitis EM; Koscik RL; Clark LR; Lu Q; Kremen WS; Franz CE; Rana B; Lyons MJ; Hogan KJ; Zhao J; Johnson SC; Engelman CD
    J Alzheimers Dis; 2021; 79(3):1041-1054. PubMed ID: 33427733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice.
    Arendash GW; Jensen MT; Salem N; Hussein N; Cracchiolo J; Dickson A; Leighty R; Potter H
    Neuroscience; 2007 Oct; 149(2):286-302. PubMed ID: 17904756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease.
    Lebbadi M; Julien C; Phivilay A; Tremblay C; Emond V; Kang JX; Calon F
    J Alzheimers Dis; 2011; 27(4):853-69. PubMed ID: 21914946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study.
    Freund Levi Y; Vedin I; Cederholm T; Basun H; Faxén Irving G; Eriksdotter M; Hjorth E; Schultzberg M; Vessby B; Wahlund LO; Salem N; Palmblad J
    J Intern Med; 2014 Apr; 275(4):428-36. PubMed ID: 24410954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined.
    Nolan JM; Mulcahy R; Power R; Moran R; Howard AN
    J Alzheimers Dis; 2018; 64(2):367-378. PubMed ID: 29945352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer's disease.
    Iuliano L; Pacelli A; Ciacciarelli M; Zerbinati C; Fagioli S; Piras F; Orfei MD; Bossù P; Pazzelli F; Serviddio G; Caltagirone C; Spalletta G
    J Alzheimers Dis; 2013; 36(3):545-53. PubMed ID: 23635405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects.
    Ciavardelli D; Piras F; Consalvo A; Rossi C; Zucchelli M; Di Ilio C; Frazzini V; Caltagirone C; Spalletta G; Sensi SL
    Neurobiol Aging; 2016 Jul; 43():1-12. PubMed ID: 27255810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty acids and beyond: Age and Alzheimer's disease related changes in lipids reveal the neuro-nutraceutical potential of lipids in cognition.
    Ooi KM; Vacy K; Boon WC
    Neurochem Int; 2021 Oct; 149():105143. PubMed ID: 34311029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.